Despite decreasing incidence, HIV is the leading cause of morbidity and mortality in Kenya. In Kisumu, HIV prevalence is 19% and incidence is second highest in the country. There is a need to identify HIV-positive persons and link them to care. Universal testing in healthcare facilities is a strategy supported by the Kenyan government to facilitate identification of new HIV cases. The objective was to identify patterns of HIV testing in a hospital in Kisumu, Kenya, a setting where universal testing is recommended. A retrospective chart review of patients seen between January 2014 and December 2014 was conducted. We collected information on 5% of admitted patients older than 18 years of age. Chi square analysis characterized patients and Poisson regression modeling produced the relative risk of being tested. In 2014, 9071 patients were admitted from the emergency unit. From the sample, 24% of patients were recorded to have been tested for HIV. There was no significant difference in testing between genders (p ¼ 0.99). Females with a genitourinary diagnosis were significantly more likely to be tested for HIV than other diagnoses (adjusted relative risk [aRR] ¼ 1.79). Males with an infectious disease were 1.86 times more likely to be tested for HIV than other diagnoses, while females with pregnancy-related diagnoses were 50% less likely to be tested for HIV (aRR ¼ 0.50). While universal testing supports a non-risk-based screening of patients, higher risk diagnoses were more likely to be tested. This study demonstrates that there is still opportunity to further practice and implement universal testing.
Introduction
Despite a reduction in HIV prevalence in Kenya from 10% of the population in 2007 to the current prevalence rate of 6.3%, HIV is still the leading cause of morbidity and mortality in Kenya. 1 Based on the 2012 Kenya AIDS Indicator Survey, 71.3% of adolescents and adults have ever been tested for HIV, with 46.9% of HIV-positive individuals aware of their status. A national strategy, Universal Access to Testing, was implemented in 2008 to reduce HIV rates through increased identification. The aim of this strategy was to stipulate HIV testing for all Kenyans regardless of their risk. The initial goal of Universal Access to Testing was to have 80% of Kenyans tested by 2011. 2 Universal Access to HIV Testing strives to identify all people with HIV and to link them to necessary care, including antiretroviral therapy. Many strategies have been implemented to test individuals for HIV. These include provider-initiated testing and counseling, voluntary counseling and testing sites, antenatal care sites, direct-to-consumer testing, and home-based testing. Universal testing at healthcare facilities is a newer recommended modality to test individuals for HIV regardless of risk. The purpose of this strategy is to remove the risk component and reduce stigma in 1 Arizona Department of Health Services, Phoenix, AZ, USA 2 University of Illinois at Chicago, Chicago, IL, USA testing. 3 Provider-initiated testing and counseling can be considered a form of universal testing.
In Kenya, the highest prevalence and incidence rates of HIV are found in Western Kenya in the Nyanza Province off the shores of Lake Victoria. Due to a restructuring of the government system in 2010, this area is now referred to as Kisumu County. The four counties with the highest HIV rates are Homa Bay, Siaya, Kisumu, and Migori with prevalence rates of 25.7, 23.7, 19.3, and 14.7%, respectively. 4 Kisumu City is the third largest city in Kenya and the headquarters of the County with a population of 968,909 (2009 National Census). In 2014, Kisumu had an estimated incidence of 10,349 (0.98%) new HIV infections among adults aged 15 years and older. 4 Kisumu City is also the location of the main teaching and referral hospital, Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) which serves Homa Bay, Siaya, Kisumu, Migori counties and beyond, a population in excess of five million. JOOTRH supports the recommended Universal Access to Testing goals, reporting an annual 80% testing target (Neubauer, 2015, personal communication).
In the setting of recommended universal testing, there are still concerns of bias for testing based on risk. Known higher risk groups may be tested more often, allowing opportunity for unsuspected HIV infections to go undiagnosed and for stigma to continue around getting tested. High risk groups include those with infectious diseases (IDs) and known coinfections, such as TB, candidiasis, hepatitis, and pneumonia. It is also known that in Kenya and throughout other sub-Saharan African countries, girls and young women are at particular risk of becoming HIV-positive. Seventy-two percent of all people aged 15-24 with HIV in sub-Saharan Africa are female. 5 Sixty percent of new HIV infections occur among children and young adults. In 2012, the prevalence of HIV among young women was 3% compared to young men at between 1.1 and 1.5%. 6 This is speculated to be a result of gender roles, where young women are getting HIV from older male partners. 7 The aim of this study is to identify patterns of HIV testing in the teaching and referral hospital in Kisumu, Kenya, a setting where universal testing is supported and recommended. We hypothesize that despite recommended testing regardless of risk, patients with the greatest risk of infection are still more likely to be tested. Characterizing how or to whom testing is being conducted is an important step to understanding how to improve universal testing in healthcare facilities.
Methods
This study was approved by the University of Illinois at Chicago Institutional Review Board and Maseno University Institutional Review Board. A retrospective chart review was conducted at JOOTRH, abstracting data from patients seen initially in the emergency unit (EU) and admitted to the hospital between 1 January 2014 and 31 December 2014. We selected a 5% sample of only admitted patient charts to obtain statistically significant data. Based on the total admissions from the EU for the year, we systematically selected a sample of admitted patients who were 18 years and older on date of admission after stratifying patient names by department. Every 20th patient chart was selected. Patient charts with differing admission dates, documentation of known or previous HIV diagnosis, intensive care unit patients, and patients with missing testing data were excluded from the data set.
Data variables collected included the first three listed EU diagnoses, date of admittance, home village, gender, and age. Diagnoses were categorized based on ICD-9 codes and were further organized into five subcategories of interest: IDs, genitourinary (GU) diagnoses, pregnancy complications, injury, and other. 'Other' includes all the other listed diagnoses and was used as the reference group. We chose to investigate GU diagnoses because of the potential sexual pathway of transmission and the perception of a riskier diagnosis. We looked at injury because it was the most frequent diagnosis, particularly in young men, and is generally not related to health status. For patients that had more than one diagnosis listed, we used hierarchy coding in the order of diagnoses listed above. For example, the IDs category would be used if a patient had both an ID diagnosis and a cardiovascular-related diagnosis. We categorized county into Kisumu, Homa Bay, Siaya, and all other counties as Other due to low numbers from the remaining ten counties listed. Our primary outcome was receiving an HIV test.
Associations between variables and the outcome of interest were explored in univariate and bivariate analyses and entered in a multivariate Poisson regression model. Log binomial regression was initially used for our model. However, as some variables failed to converge in the multivariate model, Poisson regression was required. Statistical analyses were performed using SAS 9.4 (Cary, NC). Due to different distributions and patterns of disease between men and women, we stratified the analyses by gender, but also include an aggregate analysis with gender as a covariate. Chi square tests characterized patients seen and Poisson regression modeling produced the relative risk of being tested for HIV based on EU diagnosis and covariates. The fully adjusted models included age, village, and calendar year quarter of admittance. All variables were kept due to our a priori hypothesis.
Results
A total of 9071 patients were admitted to inpatient wards from the EU. Five hundred and twelve patient charts were reviewed (5% sample). Eighty four patient charts were excluded, with a final sample size of 428 admitted patient charts (see Figure 1 ).
Univariate results
There were more females in the sample than males (n ¼ 239 and n ¼ 189, respectively). Distribution of EU diagnoses differed between males and females. Males had three times more injury diagnoses than females (33% versus 12%), while females had more GU complaints and an additional diagnosis category of pregnancy complications (see Table 1 ). The mean age of males was 45.23 years and that of females was 41.68 years (p ¼ 0.07), median ages were 40 and 35, respectively, with a range of 18-98 and 18-100, respectively. There were more females in the 18-25 age group (28% versus 16%) and more males in the 40-64 age group (29% versus 20%). The distribution of age was otherwise relatively similar. The majority of patients were from Kisumu for both males and females, followed by Siaya, Other, and Homa Bay, respectively. For males and females, roughly 30% were admitted during the fourth quarter (October, November, and December).
Bivariate results
Within the sample (n ¼ 428), 46 males were tested for HIV compared to 58 females, which resulted in 24% males, 24% females, and 24% overall. There was a significant association between EU diagnosis and being tested for HIV for females (p ¼ 0.02), but not for males.
Males 40-64 years of age had the highest rates of being tested for HIV (33%) and females aged 65þ (38%). Males from Homa Bay had the highest rates of HIV testing among the counties (33%), and for females from the Other counties (41%). For males and females, those admitted in the last quarter had the highest rates of HIV testing (32 and 31%, respectively) (see Table 2 ). Removed 38 pts with missing tesƟng data = 428 Figure 1 . Analytic sample path.
Regression analysis results
The results from the crude and adjusted regression analyses can be found in Table 3 . After controlling for all covariates, among females, those with a GU diagnosis were more likely to be tested for HIV (adjusted relative risk [aRR] ¼ 1.79 (1.00, 3.20)). After controlling for all covariates, among males, those with an ID were 1.86 (1.01, 3.43) times more likely to be tested for HIV. Conversely, among females with pregnancy-related diagnoses, they were 50% less likely to be tested for HIV (aRR ¼ 0.50 (0.21, 1.23)) (see Table 3 ). In the female crude and adjusted model, all age groups younger than the reference category of 65þ were below the null, and thus less likely to be tested for HIV. In the crude and adjusted models, the 40-64 age group for males was more likely to be tested for HIV, followed by the youngest at 18-25.
After controlling for covariates, among females, those living in Other counties were significantly more likely to be tested for HIV than in Kisumu (aRR ¼ 2.42 (1.43, 4.08)). The opposite was found among males, where Other counties were the least likely to be tested (aRR ¼ 0.42 (0.11, 1.60)). It is important to note that the distribution of Other counties varied between the two genders. For males and females, those admitted in the fourth quarter had the highest relative risk of being tested for HIV, though not statistically significant (aRR ¼ 2.39 (1.04, 5.46), 1.64 (0.96, .79), respectively) (see Table 3 ).
Discussion
We hypothesized that despite recommended testing regardless of risk, patients with the greatest risk of infection are still more likely to be tested. In our study, men with ID-related diagnoses were more likely to be tested, while women with GU-related diagnoses were more likely to be tested. This implies that people with higher risk diagnoses were more likely to be tested. However, women presenting with pregnancy complications to the EU were 50% less likely to be tested. One possible explanation may be that pregnant women receive antenatal care elsewhere and are being tested in those settings. It has been reported that 69% of pregnant women in Kenya were tested for HIV during antenatal care. 8 Additionally, young women were not more likely to be tested. In this case, higher risk testing is not supported, as one would expect that young women would be more likely to be tested due to a known higher risk for HIV infection. The application of universal testing versus targeted testing should be further evaluated in the EU to identify bias and determine potential benefits or disadvantages of testing patterns.
In our study, 24% of overall patients admitted through the EU were tested for HIV. Fewer patients are being tested per the Universal Testing goal of 80%. The lower testing rate may be a result of documentation. Although there was a designated section in the charts where HIV testing and status were meant to be documented, this was not always the case. Additionally, it was not recorded in the chart if a patient was offered a test but declined, so we do not know if more people were offered testing but chose to opt out. Some patients may have known their status and opted out of testing.
As a result, the documented rates of testing may not reflect true testing rates in the region. According to the Kenyan Demographic Health Survey, 69.6% of men and 74.7% of women ages 15-24 in the Nyanza region of Kenya had been tested for HIV in past 12 months, much higher than the reported testing rate. 8 The survey did not breakdown where people were tested. Hence, a reason for the low reported rates may be that people in Kisumu have access to many locations for HIV testing. 6 Patients that had been recently tested elsewhere did not require retesting for another 12 months.
We included time period as a covariate to see if there was any relation to seasonal disease trends or other factors that may determine testing rates. HIV testing was highest in the last quarter of the year. This may be a result of different disease patterns, seasonal accessibility issues, a demand to meet testing quotas, or the availability of testing supplies throughout the year. It is unclear why this is the case. Further exploration into this finding is warranted.
Limitations
This study has several limitations that could limit generalizability, however given the constraints of time and the quality of the patient charts, the design of the study was intended to minimize the effects on the reliability of the results. Data and variables were determined based on what was consistently available. Due to this, we were unable to assess other desirable covariates and outcomes, such as HIV test results among those who were tested, or date of last documented HIV test. Missing data due to incomplete documentation in patient records likely affected results. For instance, documentation of HIV testing was not always recorded in the charts. This may be a reason for a low documented testing rate.
The study only investigated patients who were seen in the EU and admitted because inpatient charts were the only reliably available charts. This population is presumably sicker than nonadmitted patients. Generalizability of our findings may be improved if charts of nonadmitted patients were available.
Coding and subsequent subcategorization were broad. As categorized, kidney failure fell in the same category as a urinary tract infection (UTI), GU diseases. Kidney failure and UTI may carry different risks for having HIV and being tested for HIV. Categorizing diseases differently potentially may affect our results.
Future direction
To conclude, universal testing may capture a greater number of new HIV infections, though targeted testing may also be necessary to reinforce that highest risk groups are among those being tested. 9 Monitoring of who is being tested is important in order to recognize gaps in universal testing, reinforce the mandate, and improve processes. For instance, our findings highlight a need to investigate why young women, one of the highest risk groups, are being tested less than other groups.
Our findings may be strengthened if testing data are prospectively collected and include both admitted and nonadmitted EU data. In addition to the current variables collected, data could include whether a test is offered, if and why it is declined, the results, and where else or when was the last time the patient was tested. Understanding patterns and further delineating bias, even in a setting where universal testing is supported and recommended, will help to address gaps in achieving the mandate. In addition, further monitoring of who, where, and how testing is conducted and documented will facilitate compliance with the universal testing mandate.
